MaxCyte has signed a development and commercialisation agreement for multiple therapies with KSQ Therapeutics (KSQ), the seventh such deal to be signed over the last 15 months, and the eighth since its IPO in March 2016.
04 Dec 2019
Commercial licence agreement with KSQ
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Commercial licence agreement with KSQ
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
04 Dec 2019 -
Author:
Mick Cooper PhD -
Pages:
2
MaxCyte has signed a development and commercialisation agreement for multiple therapies with KSQ Therapeutics (KSQ), the seventh such deal to be signed over the last 15 months, and the eighth since its IPO in March 2016.